Genetic and structural analysis of HIV-1 rev responsive element related to V38A and T18A enfuvirtide resistance mutations

Intervirology

Volumn 55, Issue 5, 2012, Pages 385-390

  Dimonte, Salvatore ^a   Mercurio, Fabio ^a   Svicher, Valentina ^a   Perno, Carlo Federico ^a,b   Ceccherini Silberstein, Francesca ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

gp41; HIV; Mutagenetic tree; Mutations; Rev Responsive Element (RRE); RNA; Structure

Indexed keywords

ENFUVIRTIDE;

ANTIVIRAL RESISTANCE; ARTICLE; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REV RESPONSIVE ELEMENT GENE; VIRUS GENE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BASE PAIRING; DRUG RESISTANCE, VIRAL; GENES, ENV; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; NUCLEIC ACID CONFORMATION; PEPTIDE FRAGMENTS; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861455495     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000334696     Document Type: Article

References (37)

1. Saliou JM, Bourgeois CF, Ayadi-Ben ML, Ropers D, Jacquenet S, Marchand V, Stevenin J, Branlant C: Role of RNA structure and protein factors in the control of HIV-1 splicing. Front Biosci 2009; 14: 2714-2729.
2. Cullen BR: Nuclear mRNA export: insights from virology. Trends Biochem Sci 2003; 28: 419-424.
3. Kjems J, Brown M, Chang DD, Sharp PA: Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element. Proc Natl Acad Sci USA 1991; 88: 683-687.
4. Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M: Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 2005; 79: 764-770.
5. Greenberg M, Cammack N, Salgo M, Smiley L: HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004; 14: 321-337.
6. Miller MD, Hazuda DJ: HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist Updat 2004; 7: 89-95.
7. Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML: Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005; 79: 12447-12454.
8. Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW: Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79: 4991-4999.
9. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005; 49: 1113-1119.
10. Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF: Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006; 58: 714-722.
11. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD: Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156-163.
12. Ueno M, Kodama EN, Shimura K, Sakurai Y, Kajiwara K, Sakagami Y, Oishi S, Fujii N, Matsuoka M: Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Res 2009; 82: 67-72.
13. Svicher V, Alteri C, D'Arrigo R, Lagana A, Trignetti M, Lo CS, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, Di PG, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F: Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. Antimicrob Agents Chemother 2009; 53: 2816-2823.
14. Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di Perri G, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF: Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. J Infect Dis 2008; 197: 1408-1418.
15. Poveda E, Rodes B, Toro C, Martin-Carbonero L, Gonzalez-Lahoz J, Soriano V: Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002; 16: 1959-1961.
16. Poveda E, Rodes B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V: Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol 2005; 34: 295-301.
17. Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardiere JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F: Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006; 80: 8807-8819.
18. Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V: Dynamics of drugresistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. AIDS Res Hum Retroviruses 2007; 23: 1078-1082.
19. Loutfy MR, Raboud JM, Montaner JS, Antoniou T, Wynhoven B, Smaill F, Rouleau D, Gill J, Schlech W, Brumme ZL, Mo T, Gough K, Rachlis A, Harrigan PR, Walmsley SL: Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide. Antiviral Res 2007; 75: 58-63.
20. Cardoso LP, Stefani MM: High level of multidrug resistance mutations in HIV type 1 pol gene and resistance-associated mutations to enfuvirtide (T-20) among antiretroviral- experienced patients from central Brazil. AIDS Res Hum Retroviruses 2009; 25: 943-950.
21. Razzolini F, Vicenti I, Saladini F, Micheli V, Romano L, Cargnel A, Zazzi M: Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy. AIDS Res Hum Retroviruses 2007; 23: 558-563.
22. Hudelson SE, Marlowe N, Huang W, Bruce R, Church JD, Husnik M, Donnell D, Coates T, Jackson JB, Chesney M, Koblin B, Eshleman SH: Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors. AIDS Res Hum Retroviruses 2009; 25: 701-705.
23. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The CLUSTALX windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25: 4876-4882.
24. Hall TA: BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999; 41: 95-98.
25. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-1599.
26. Su C, Melby T, Demasi R, Ravindran P, Heilek- Snyder G: Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J Clin Virol 2006; 36: 249-257.
27. Do CB, Woods DA, Batzoglou S: CONTRAfold: RNA secondary structure prediction without physics-based models. Bioinformatics 2006; 22:e90-e98.
28. Watts JM, Dang KK, Gorelick RJ, Leonard CW, Bess JW Jr, Swanstrom R, Burch CL, Weeks KM: Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 2009; 460: 711-716.
29. Sato K, Hamada M, Asai K, Mituyama T: CENTROIDFOLD: a web server for RNA secondary structure prediction. Nucleic Acids Res 2009; 37:W277-W280.
30. Holland SM, Ahmad N, Maitra RK, Wingfield P, Venkatesan S: Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure. J Virol 1990; 64: 5966-5975.
31. Cook KS, Fisk GJ, Hauber J, Usman N, Daly TJ, Rusche JR: Characterization of HIV-1 REV protein: binding stoichiometry and minimal RNA substrate. Nucleic Acids Res 1991; 19: 1577-1583.
32. Iwai S, Pritchard C, Mann DA, Karn J, Gait MJ: Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein. Nucleic Acids Res 1992; 20: 6465-6472.
33. Kirby DA, Muse SV, Stephan W: Maintenance of pre-mRNA secondary structure by epistatic selection. Proc Natl Acad Sci USA 1995; 92: 9047-9051.
34. Wilke CO, Lenski RE, Adami C: Compensatory mutations cause excess of antagonistic epistasis in RNA secondary structure folding. BMC Evol Biol 2003; 3: 3.
35. Kern AD, Kondrashov FA: Mechanisms and convergence of compensatory evolution in mammalian mitochondrial tRNAs. Nat Genet 2004; 36: 1207-1212.
36. Beerenwinkel N, Rahnenfuhrer J, Kaiser R, Hoffmann D, Selbig J, Lengauer T: Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics 2005; 21: 2106-2107.
37. Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V: Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004; 74: 21-28.